# Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma

> **NCT02767674** · PHASE3 · UNKNOWN · sponsor: **The First Affiliated Hospital with Nanjing Medical University** · enrollment: 258 (estimated)

## Conditions studied

- Diffuse Large B Cell Lymphoma

## Interventions

- **DRUG:** Rituximab
- **DRUG:** Gemcitabine
- **DRUG:** Oxaliplatin
- **DRUG:** Cyclophosphamide
- **DRUG:** Epirubicin Injectable Product
- **DRUG:** Vindesine
- **DRUG:** Prednisone

## Key facts

- **NCT ID:** NCT02767674
- **Lead sponsor:** The First Affiliated Hospital with Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-05
- **Primary completion:** 2020-12
- **Final completion:** 2020-12
- **Target enrollment:** 258 (ESTIMATED)
- **Last updated:** 2019-01-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02767674

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02767674, "Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02767674. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*